EM2406H "Cardiovascular Disease Prevention Among PWH in 2024: Lessons from the REPRIEVE Trial" (IM GR-062824)
Purpose and Overview
Purpose and Overview: The purpose of this lecture is to outline the specific presentation mechanisms and treatment strategies to prevent cardiovascular disease among PWH in 2024. Lessons learned from the REPRIEVE trial now form the basis of recent AHA/ACC/DHHS recommendations, which will be discussed in detail.
Target Audience
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- 1. What is the main cause of cardiovascular disease (CVD) in people with HIV (PWH)?
- 2. Know the rationale of the REPRIEVE Trial, REPRIEVE’s primary findings and their impact for the care of PWH globally
- 3. Appreciate the unique phenotype of CVD in PWH, novel mechanisms of CVD, and the effects of statins on plaque and key biomarkers
Steven Grinspoon M.D.
Professor of Medicine
Division of Nutrition
Harvard Medical School
Available Credit
- 1.00 AMA
Price
Required Hardware/software
Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome